Navigation Links
MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
Date:10/16/2008

Second Agreement Signed in Third Quarter of 2008 Expands Worldwide

Application of Cutting-Edge Influenza Vaccine Technology

GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.

"Omninvest has demonstrated decades of commitment to providing protection against influenza, and we commend their commitment to donate some of their product to the World Health Organization (WHO) stockpile for distribution among developing nations," said MedImmune's Jonathan Klein-Evans, vice president, intellectual property. "MedImmune is pleased to license our reverse genetics technology to Omninvest as we have done previously to five other influenza vaccine manufacturers."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the rev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
2. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
6. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
7. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
8. Seneca Valley High School Student Receives Science Award From MedImmune
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... PHOENIX, Nov. 12 Arizona Heart Innovative Technologies,LLC (AHIT) ... endovascular,use to a publicly traded medical device company. "This ... the past ten months. We,continue to demonstrate our ability ... community to commercially viable products for medical,device companies. This ...
... Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), a ... will announce its third quarter 2008,financial and operating ... a.m.,The Company will host a conference call and ... at 10:00 a.m., Eastern Time., Participants may ...
... Novavax, Inc.,(Nasdaq: NVAX ) a clinical-stage vaccine ... Executive Officer, will be presenting at,the Lazard Capital Markets ... 19, 2008 at the St. Regis Hotel, New York ... strategy, research and,development progress. A link to the live ...
Cached Biology Technology:Arizona Heart Innovative Technologies Licenses New Endovascular Device 2
(Date:7/11/2014)... including scientists from the Max Planck Institute for Medical ... step in understanding photosynthesis, the process by which the ... its atmosphere and which is therefore crucial for all ... researchers report the first direct visualization of a crucial ... which a specific protein complex, photosystem II, splits water ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... ill, or suffered an injury, you,ve watched gloomily as your ... about as common to the human condition as breathing. ... causes skeletal muscles to atrophy. They know proteins are responsible, ... key actors from the poseurs is tricky. In a ...
... the atmosphere are rising; the average temperatures of the ... these changes. The transitional zones between shallow shelf seas ... huge amount of methane hydrates in the sea bed. ... and under high pressure. When the water temperature directly ...
... linked to type 2 diabetes have been discovered by an ... The study provides a fuller picture of the genetics ... patterns emerging. The international team, led by researchers ... and MIT, and the University of Michigan, Ann Arbor, used ...
Cached Biology News:Researchers identify key culprit causing muscle atrophy 2Researchers identify key culprit causing muscle atrophy 3Are methane hydrates dissolving? 210 new diabetes gene links offer picture of biology underlying disease 210 new diabetes gene links offer picture of biology underlying disease 3
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ANTI GELSOLIN...
Biology Products: